24 July 2019
When do clinical trial consent disclosures render a patent invalid?
www.twobirds.com/en/news/articles/2019/australia/when-do-clinical-trial-consent-disclosures-render-a-patent-invalid

In the recent case of InterPharma Pty Ltd v Hospira Inc (No 5) [2019] FCA 960 the Australian Federal Court has given patentees guidance as to novelty preserving practice in the conduct of clinical trials.

21 April 2020
COVID-19 (Temporary Measures) Act 2020 Update: Applicable Duration and Regulations to Obtain Temporary Contractual Relief in Singapore
www.twobirds.com/en/news/articles/2020/singapore/covid-19-temporary-measures-act-2020-update-applicable-duration-and-regulations

Following our previous article (COVID-19 (Temporary Measures) Act 2020: Legal circuit breaker), a number of regulations were introduced on 20 April 2020 which sets out the relevant details and processes for a party ...

06 February 2020
The Payment Services Act of Singapore
www.twobirds.com/en/news/articles/2020/singapore/the-payment-services-act-of-singapore

The payment services landscape globally and in Singapore has transformed considerably in recent years. In adapting to these changes, the Monetary Authority of Singapore (MAS) promulgated the Payment Services Act (PS ...

08 June 2018
Regulatory Changes for Medical Devices in Singapore
www.twobirds.com/en/news/articles/2018/singapore/regulatory-changes-for-medical-devices-in-singapore

On 22 May 2018, the Health Sciences Authority (the "HSA") issued a press release announcing changes to the regulatory process for medical devices ("MDs").

23 April 2020
COVID-19: Our series of regulatory legislation trackers for the Life Sciences & Healthcare industry
www.twobirds.com/en/news/articles/2020/global/covid-19-our-series-of-regulatory-legislation-trackers-for-the-life-sciences-and-healthcare-industry

COVID-19 presents an unprecedented challenge to the global life sciences industry. Members of our International Life Sciences & Healthcare team, lawyers who have a wealth of hands-on experience and strong relationships ...

03 December 2020
The Legal 500: Pharmaceutical Advertising Country Comparative Guide
www.twobirds.com/en/news/articles/2020/global/the-legal-500-pharmaceutical-advertising-country-comparative-guide

The Legal 500: Pharmaceutical Advertising Guide 2021 is a practical cross-border insight into pharmaceutical advertising, with contributing editor Sally Shorthose.

13 February 2020
The new [email protected] Programme
www.twobirds.com/en/news/articles/2020/singapore/the-new-tech-at-sg-programme

The Economic Development Board (EDB) and Enterprise Singapore (ESG) have recently rolled out the [email protected] Programme which is designed to facilitate the hire of highly skilled foreign talent by qualifying technology firms ...

12 February 2020
Amendments to the quarterly reporting framework and enhancements to continuous disclosures under the listing manual
www.twobirds.com/en/news/articles/2020/singapore/amendments-to-the-quarterly-reporting-framework-and-enhancements-to-continuous-disclosures

On 9 January 2020, the Singapore Exchange Regulation announced that amendments will be made to the quarterly reporting framework and enhancements will be made to continuous disclosures under the Listing Rules ...

12 October 2020
How are vertical agreements regulated in Australia?
www.twobirds.com/en/news/articles/2020/australia/how-are-vertical-agreements-regulated-in-australia

Unlike the Vertical Agreements Block Exemption Regulation in the EU, Australia's Competition and Consumer Act 2010 (Cth) (‘CCA’) does not regulate vertical restraints or vertical conduct through a single legislative ...

11 May 2020
Australia: While COVID-19 lockdown restrictions ease enforcement of advertising restrictions for therapeutic goods tighten
www.twobirds.com/en/news/articles/2020/australia/australia-while-covid-19-lockdown-restrictions-ease-enforcement-of-advertising-restrictions

The Therapeutic Goods Administration (TGA) has been monitoring and taking action against individuals and companies capitalising on the current pandemic to market and sell products that claim to prevent or cure COVID-19.